Delivering automated RNA workflows to significantly reduce cost per sample and hands-on time using microfluidics technology SOUTH SAN FRANCISCO, Calif. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life
SOUTH SAN FRANCISCO, Calif. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report third quarter 2019 financial results on Tuesday,
Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Industry-Leading CyTOF Technology Recognized at the 18th Annual HUPO World Congress for Delivering Unprecedented Proteomic Insight at Single-Cell Resolution SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Human Proteome Organization (HUPO), an international scientific
SOUTH SAN FRANCISCO, Calif. , Sept. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has filed new legal action in the United States District Court
Fluidigm Showcases Immuno-Oncology Imaging Innovations at WMIC to Advance Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in highly multiplexed single-scan tissue imaging, today
Mount Sinai selects Fluidigm single-cell microfluidics systems to identify epigenetic changes from environmental agents in study funded by the U.S. Department of Defense SOUTH SAN FRANCISCO, Calif. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
SOUTH SAN FRANCISCO, Calif. , Aug. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor
Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal Markers and Imaging Mass Cytometry Panel Kits, Advanced CyTOF Software Introduction of Nanoscale Automated RNA-Seq NGS
